Centre For Probe Development And Commercialization
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.imagingprobes.ca/
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 3
1 (50.0%)Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.
Phase 3
Completed
- Conditions
- Prostate Cancer RecurrentRecurrent Prostate Cancer
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 100
- Registration Number
- NCT04644822
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: [I-124]-CPD-1028 InjectionBiological: CPD-1061
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2016-10-18
- Target Recruit Count
- 2
- Registration Number
- NCT02134340
- Locations
- 🇨🇦
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
🇨🇦Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Sunnybrook Health Science Centre - Odette Cancer Centre, Toronto, Ontario, Canada
A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function
Completed
- Conditions
- Renal Function Impairment
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2014-04-09
- Target Recruit Count
- 6
- Registration Number
- NCT01496391
- Locations
- 🇨🇦
St. Joesph's Healthcare Hamilton, Hamilton, Ontario, Canada
News
No news found